Phase I Study in China - Tolerability of a Single Dose of Abatacept 30 mg/kg
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether abatacept at a dose 30 mg/kg via
intravenous infusion is safe and well tolerated in the treatment of lupus nephritis in
mainland Chinese subjects with systemic lupus erythematosus (SLE)